From Medscape Diabetes & Endocrinology

Coverage from the

American Diabetes Association (ADA) 83rd Scientific Sessions

June 22 - 26, 2023; San Diego, California and virtual

June 22 - 26, 2023 San Diego, California and virtual
  • ADA 2023 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells Engraftment of Vertex Pharmaceutical's VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.
  • ADA 2023 Triple Agonist Retatrutide Hits New Weight-Loss Highs Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.
  • ADA 2023 OASIS and PIONEER PLUS Support High-Dose Oral Semaglutide Higher doses of oral semaglutide (25 mg and 50 mg) seem to be effective in type 2 diabetes and obesity, improving upon results obtained with currently approved maximum dose of oral semaglutide 14 mg daily.

Conference News

Medscape Diabetes©  WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News From ADA 2022

Previous Coverage